SULT2B1: Potential Drug Target and Biomarker for Alzheimer's and Cancer

Target Name: SULT2B1

NCBI ID: G6820

SULT2B1

SULT2B1: Potential Drug Target and Biomarker for Alzheimer's and Cancer

SULT2B1 (ARCI14) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the SULT family of proteins, which are known for their role in the detoxification of xenobiotics, such as drugs and other harmful substances. SULT2B1 has been shown to play a role in the regulation of a variety of cellular processes, including cell signaling, DNA replication, and stress response.

One of the unique features of SULT2B1 is its ability to interact with a variety of different proteins, including transcription factors, DNA-binding proteins, and histone modifiers. This makes it a potentially interesting drug target, as it may be able to modulate the activity of these proteins and have a variety of different effects on cellular behavior.

SULT2B1 has also been shown to be involved in a variety of cellular signaling pathways, including the PI3K/Akt signaling pathway, the mTOR signaling pathway, and the NF-kappa-B signaling pathway. This suggests that it may be involved in the regulation of a wide range of cellular processes, including cell growth, differentiation, and stress response.

In addition to its potential role in cellular signaling, SULT2B1 is also of interest as a potential biomarker for a variety of diseases. For example, it has been shown to be elevated in the brains of individuals with Alzheimer's disease, and may be a potential diagnostic biomarker for this disease. It is also potential target for some diseases, such as cancer, due to its role in stress response and cell signaling.

SULT2B1 is also a potential drug target for some diseases, such as cancer. Studies have shown that SULT2B1 has been expressed in a variety of cancer tissues, and that it may be involved in the regulation of cellular processes that are important for cancer growth and progression . For example, SULT2B1 has been shown to be involved in the regulation of the topoisomerase 2 (T-DNA) gene, which is involved in the maintenance of genetic stability in cancer cells.

In conclusion, SULT2B1 is a protein that has been shown to play a variety of roles in cellular signaling and DNA replication. It is a potential drug target and biomarker for a variety of diseases, including cancer. Further research is needed to fully understand its role in these processes and its potential as a therapeutic target.

Protein Name: Sulfotransferase Family 2B Member 1

Functions: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation. Responsible for the sulfation of cholesterol (PubMed:19589875, PubMed:12145317). Catalyzes sulfation of the 3beta-hydroxyl groups of steroids, such as, pregnenolone and dehydroepiandrosterone (DHEA) (PubMed:9799594, PubMed:12145317, PubMed:21855633, PubMed:16855051). Preferentially sulfonates cholesterol, while it has also significant activity with pregnenolone and DHEA (PubMed:12145317, PubMed:21855633). Plays a role in epidermal cholesterol metabolism and in the regulation of epidermal proliferation and differentiation (PubMed:28575648)

The "SULT2B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SULT2B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets